多基因评分预测术后恶心呕吐:回顾性衍生与验证队列研究
本研究基于密歇根医学和范德堡大学医学中心的全麻手术患者数据,开展全基因组关联研究并构建术后恶心呕吐(PONV)多基因风险评分,在验证队列中评估其预测价值。结果显示,标准化多基因评分与PONV风险独立相关,但遗传影响远小于临床危险因素,且对模型区分度的改善有限,临床实用性不足。
要点
- 多基因评分每增加1个标准差,PONV风险仅增加约2-3%,临床意义有限。
- 遗传因素对PONV的影响比既往PONV或晕动症、偏头痛史、女性等临床因素小一个数量级以上。
- 多基因评分虽可轻微改善模型区分度(c-statistic 0.616 vs 0.613),但不足以指导临床决策。
核心结论
- 标准化多基因风险与PONV在所有三个模型中均相关,但遗传影响小于临床危险因素,且多基因评分未显著改善区分度,不具临床实用性。
研究设计与样本
- 回顾性衍生与验证队列研究,纳入密歇根医学和范德堡大学医学中心全麻手术患者,总样本64,523例,其中5,703例发生PONV(8.8%)。
主要发现
- 发现46个遗传变异超过P<1×10-5阈值,次要等位基因频率>1%,且在两个队列中效应一致。
- 标准化多基因评分与PONV的关联:基础模型(调整年龄和性别)OR=1.027(95%CI 1.001-1.053,P=0.044);基于已知临床风险的模型OR=1.029(95%CI 1.003-1.055,P=0.030);全临床回归模型(调整21个人口学、手术和麻醉因素)OR=1.029(95%CI 1.002-1.056,P=0.033)。
- 多基因评分加入基于已知临床风险因素的模型后,整体区分度从c-statistic 0.613提高至0.616(P=0.028),净重分类改善4.6%的病例。
- 多基因风险评分高于均值1个标准差的患者,发生PONV的比值比基线人群高2-3%,但该增加幅度比既往PONV或晕动症(55%)、偏头痛史(17%)、女性(83%)的影响小至少一个数量级。
临床怎么用
- 多基因评分对PONV预测的临床价值有限,不建议用于指导临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative nausea and vomiting (PONV) is a key driver of unplanned admission and patient satisfaction after surgery. Because traditional risk factors do not completely explain variability in risk, this study hypothesized that genetics may contribute to the overall risk for this complication. The objective of this research is to perform a genome-wide association study of PONV, derive a polygenic risk score for PONV, assess associations between the risk score and PONV in a validation cohort, and compare any genetic contributions to known clinical risks for PONV. METHODS: Surgeries with integrated genetic and perioperative data performed under general anesthesia at Michigan Medicine (Ann Arbor, Michigan) and Vanderbilt University Medical Center (Nashville, Tennessee) were studied. PONV was defined as nausea or emesis occurring and documented in the postanesthesia care unit. In the discovery phase, genome-wide association studies were performed on each genetic cohort, and the results were meta-analyzed. Next, the polygenic phase assessed whether a polygenic score, derived from genome-wide association study in a derivation cohort from Vanderbilt University Medical Center, improved prediction within a validation cohort from Michigan Medicine, as quantified by discrimination (c-statistic) and net reclassification index. RESULTS: Of 64,523 total patients, 5,703 developed PONV (8.8%). The study identified 46 genetic variants exceeding the threshold of P < 1 × 10-5, occurring with minor allele frequency greater than 1%, and demonstrating concordant effects in both cohorts. Standardized polygenic score was associated with PONV in a basic model, controlling for age and sex (adjusted odds ratio, 1.027 per SD increase in overall genetic risk; 95% CI, 1.001 to 1.053; P = 0.044), a model based on known clinical risks (adjusted odds ratio, 1.029; 95% CI, 1.003 to 1.055; P = 0.030), and a full clinical regression, controlling for 21 demographic, surgical, and anesthetic factors, (adjusted odds ratio, 1.029; 95% CI, 1.002 to 1.056; P = 0.033). The addition of polygenic score improved overall discrimination in models based on known clinical risk factors (c-statistic, 0.616 compared to 0.613; P = 0.028) and improved net reclassification of 4.6% of cases. CONCLUSIONS: Standardized polygenic risk was associated with PONV in all three of the study's models, but the genetic influence was smaller than exerted by clinical risk factors. Specifically, a patient with a polygenic risk score greater than 1 SD above the mean has 2 to 3% greater odds of developing PONV when compared to the baseline population, which is at least an order of magnitude smaller than the increase associated with having prior PONV or motion sickness (55%), having a history of migraines (17%), or being female (83%) and is not clinically significant. Furthermore, the use of a polygenic risk score does not meaningfully improve discrimination compared to clinical risk factors and is not clinically useful.
引用
- Douville NJ, Bastarache L, He J, et al. Polygenic Score for the Prediction of Postoperative Nausea and Vomiting: A Retrospective Derivation and Validation Cohort Study. Anesthesiology. 2025. PMID: 39250560. doi:10.1097/ALN.0000000000005214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。